POAI News and Press, Predictive Oncology Inc. From 11/14/23

2023-11-14 13:27:15 ET Predictive Oncology Inc. (POAI) Q3 2023 Earnings Conference Call November 14, 2023, 08:30 AM ET Company Participants Glenn Garmont - IR Raymond Vennare - CEO and Chairman Josh Blacher - CFO Conference Call Participants Present...

Predictive Oncology (NASDAQ: POAI) , a science-driven company leveraging its proprietary artificial intelligence (“AI”) and machine-learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable dr...

2023-11-14 07:19:46 ET More on Predictive Oncology Financial information for Predictive Oncology For further details see: Predictive Oncology GAAP EPS of -$0.78, revenue of $0.72M

PITTSBURGH, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate onco...

Predictive Oncology Inc. (POAI) is expected to report for Q1 2024

2023-11-13 09:41:06 ET Major earnings expected before the bell on Tuesday include: Canadian Solar ( CSIQ ) The Home Depot ( HD ) Sea ( SE ) Vodafone Group Public ( VOD ) Workhorse Group ( WKHS ) For further details see: Notable earnings be...

Predictive Oncology (NASDAQ: POAI) , a leader in artificial intelligence (“AI”)-driven drug discovery and biologics, has completed a multiyear study through a partnership with UPMC Magee-Womens Hospital. The study was focused on evaluating the use of AI in building multiomic machine...

PITTSBURGH, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that it has completed a multi-year study with UPMC Magee-Womens Hospital. The objective of the study was to evaluate the use of AI to build mu...

Predictive Oncology (NASDAQ: POAI) , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Pr...

EAGAN, Minn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) ...